4978
ReproCELL Incorporated
株式会社リプロセル
Healthcare · Biotechnology
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes. The company also provides Alvetex 3D, a cell culture system; Alvetex, an advanced tissue bioengineering system; EZSPHERE Multiwell Dishes and Plates; KOKEN atelocollagen; ABLE Biott bioreactor systems; and 2mag stirrer systems. In addition, It offers research stem cell, genomics, clinical stem cell research, preclinical and drug discovery CRO, precision medicine, human tissue samples, clinical laboratory, and gene editing services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.
Read more
← Companies
Overview
Filings & Signals
Ownership
Financials
▾ Collapse Charts
Income Statement
Balance Sheet
Cash Flow
Ratios & Per Share
Metric
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Net Sales
¥3.0B
¥2.4B
¥3.0B
¥2.2B
Cost of Sales
¥1.3B
¥1.3B
¥1.8B
¥1.4B
Gross Profit
¥1.6B
¥1.1B
¥1.1B
¥803M
SG&A
¥1.8B
¥1.5B
¥1.5B
¥1.5B
Operating Income
¥-130M
¥-409M
¥-356M
¥-647M
Non-Operating Income
¥202M
¥459M
¥242M
¥206M
Interest Income
¥67M
¥51M
¥43M
¥9M
Non-Operating Expenses
¥27M
¥9M
¥6M
¥66M
Interest Expense
—
—
¥0M
¥0M
Ordinary Income
¥45M
¥40M
¥-120M
¥-507M
Pre-tax Income
¥45M
¥-29M
¥-304M
¥-574M
Income Taxes
¥-58M
¥3M
¥2M
¥1M
Current Tax
¥-2M
¥3M
¥2M
¥2M
Deferred Tax
¥-57M
¥-0M
¥-0M
¥-0M
Net Income (owners)
¥103M
¥-31M
¥-305M
¥-575M
Minority Interest
—
—
—
¥-0M
Comprehensive Income
¥-57M
¥136M
¥-287M
¥-568M
EBITDA
¥-80M
¥-372M
¥-307M
¥-587M
Goodwill Amort. (J-GAAP)
¥3M
¥3M
¥3M
¥3M
EPS
¥1.11
¥-0.37
¥-3.62
¥-7.57
Shares Outstanding
94.7M
88.9M
85.1M
82.2M
Shares Issued (total)
94.8M
89.0M
85.1M
82.3M
Treasury Shares
0.1M
0.1M
0.0M
0.0M
Metric
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Total Assets
¥9.7B
¥9.1B
¥8.4B
¥8.1B
Current Assets
¥4.9B
¥7.4B
¥7.2B
¥5.4B
Cash & Deposits
¥2.8B
¥2.9B
¥1.9B
¥2.6B
Trade Receivables
¥464M
¥421M
¥446M
¥348M
Non-Current Assets
¥4.8B
¥1.7B
¥1.2B
¥2.7B
PP&E
¥242M
¥200M
¥101M
¥98M
Goodwill
¥8M
¥11M
¥14M
¥16M
Intangible Assets
¥27M
¥24M
¥15M
¥29M
Investment Securities
¥4.4B
¥1.4B
¥1.0B
¥2.5B
Deferred Tax Assets
¥55M
—
—
—
Total Liabilities
¥686M
¥741M
¥781M
¥845M
Current Liabilities
¥641M
¥678M
¥750M
¥827M
ST Debt
—
—
—
¥80M
Taxes Payable
¥25M
¥27M
¥27M
¥5M
Non-Current Liabilities
¥45M
¥63M
¥31M
¥17M
Deferred Tax Liab.
¥35M
¥54M
¥23M
¥10M
Total Equity
¥9.0B
¥8.3B
¥7.6B
¥7.3B
Capital Stock
¥2.7B
¥2.3B
¥2.0B
¥1.7B
Capital Surplus
¥6.2B
¥6.4B
¥6.1B
¥6.3B
Retained Earnings
¥58M
¥-547M
¥-515M
¥-750M
Treasury Stock
¥-1M
¥-1M
¥-1M
¥-1M
AOCI
¥-6M
¥154M
¥-14M
¥-32M
Equity (owners)
¥9.0B
¥8.2B
¥7.6B
¥7.3B
Total Interest-Bearing Debt ⓘ
—
—
—
¥80M
Net Cash ⓘ
¥2.8B
¥2.9B
¥1.9B
¥2.6B
NCAV ⓘ
¥4.2B
¥6.7B
¥6.4B
¥4.5B
NCAV/Share
¥44
¥75
¥75
¥55
BV/Share
¥95
¥92
¥89
¥88
Metric
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
Operating CF
¥6M
¥-11M
¥-141M
¥-246M
Interest Paid
—
—
¥-0M
¥-0M
Interest Received
¥63M
¥51M
¥43M
¥9M
D&A
¥48M
¥34M
¥46M
¥57M
Goodwill Amort.
¥3M
¥3M
¥3M
¥3M
Investing CF
¥-796M
¥404M
¥-1.1B
¥-2.1B
CapEx
¥87M
¥171M
¥150M
¥43M
Financing CF
¥680M
¥544M
¥483M
¥2.4B
Share Buybacks
—
¥0M
¥0M
¥-0M
LT Debt Repaid
—
—
¥-80M
—
Free Cash Flow
¥-80M
¥-183M
¥-291M
¥-290M
Net Change in Cash
¥-116M
¥1.0B
¥-722M
¥36M
Metric
FY 2024
EDINET ↗
FY 2023
EDINET ↗
FY 2022
EDINET ↗
FY 2021
EDINET ↗
ROE
1.2%
-0.4%
-4.1%
-7.9%
ROA
1.1%
-0.4%
-3.7%
-7.1%
EPS
¥1.11
¥-0.37
¥-3.62
¥-7.57
BPS
¥94.89
¥93.41
¥89.01
¥88.11
FCF/Share
¥-1
¥-2
¥-3
¥-4
NCAV/Share
¥44
¥75
¥75
¥55
Event Timeline
S Shareholder
A Capital Signal
▾ Hide Chart
Large Shareholder Reports 6
Date Activist Stake Event Flag Demands Source
2024-07-19
Morgan Stanley MUFG Securities Co., Ltd.
4.03%
-1.72%
change
Passive
—
2024-07-04
Morgan Stanley MUFG Securities Co., Ltd.
5.75%
-1.09%
change
Passive
—
2024-04-19
Morgan Stanley MUFG Securities Co., Ltd.
6.84%
-1.12%
change
Passive
—
2024-03-06
Morgan Stanley MUFG Securities Co., Ltd.
7.96%
-1.7%
change
Passive
—
2024-01-31
Morgan Stanley MUFG Securities Co., Ltd.
9.66%
-1.21%
change
Passive
—
2023-12-27
Morgan Stanley MUFG Securities Co., Ltd.
10.87%
initial_5pct
Passive
—
Top 10 Shareholders
Ownership DNA
Cross-Holdings Tracker 1
#
Shareholder
Shares (thou.)
% of Total
1
楽天証券株式会社
1,504,600
1.58%
2
BNY Mellon (Nominee)
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS MLSCB RD (常任代理人 株式会社三菱UFJ銀行)
1,128,891
1.19%
3
横山 周史
1,106,950
1.16%
4
上田八木短資株式会社
1,000,000
1.05%
5
五十畑 輝夫
828,600
0.87%
6
中野 暁
700,000
0.73%
7
State Street Bank and Trust Company
STATE STREET BANK AND TRUST COMPANY 505223 (常任代理人 株式会社みずほ銀行)
683,200
0.72%
8
JPモルガン証券株式会社
654,495
0.69%
9
中辻 憲夫
500,000
0.52%
10
椎橋 正則
470,800
0.49%
Domestic Nominees
0.0%
+0.0% vs 2024
Trust bank custodians — GPIF, pensions, investment trusts
Foreign Custodians
1.9%
+1.9% vs 2024
Sub-custodians for foreign asset managers
Direct / Strategic
7.1%
-0.6% vs 2024
Named entities with disclosed investment intent
Shareholder
Trend
2023
2024
2025
楽天証券
—
1.14%
1.58%
+0.44%
BNY Mellon
NEW ENTRY
—
—
—
1.19%
NEW
横山 周史
1.19%
1.15%
1.16%
+0.01%
上田八木短資
1.17%
1.12%
1.05%
-0.07%
五十畑 輝夫
0.96%
0.92%
0.87%
-0.05%
中野 暁
0.68%
0.76%
0.73%
-0.03%
State Street
NEW ENTRY
—
—
—
0.72%
NEW
JPモルガン証券
NEW ENTRY
—
—
—
0.69%
NEW
中辻 憲夫
0.58%
0.56%
0.52%
-0.04%
椎橋 正則
—
0.52%
0.49%
-0.03%
式会社日本生物材料センター
last seen 2024
Exited Top 10
—
0.52%
—
荒井 憲一
last seen 2024
Exited Top 10
—
0.51%
—
大和証券
last seen 2024
Exited Top 10
—
0.49%
—
式会社SBI証券
last seen 2023
Exited Top 10
2.09%
—
—
松井証券
last seen 2023
Exited Top 10
1.26%
—
—
セントラル短資
last seen 2023
Exited Top 10
1.14%
—
—
式会社SBIネオトレード証券
last seen 2023
Exited Top 10
0.41%
—
—
藤井 衛
last seen 2023
Exited Top 10
0.40%
—
—
Concentration (HHI)
ⓘ
12
7
9
3 fiscal years · top-10 holders per year · >2,500 HHI = high concentration · entity-resolved
Portfolio Book Value
¥87M
-10% since 2023
Holdings
1
Trend
Stable
vs 2023
Held Company
FY2025
¥87M total
FY2023
¥98M total
Book Val ¥M
Shares
Book Val ¥M
Shares
Kringle Pharma,Inc.
クリングルファーマ(株)
87
100,000
98
100,000
Portfolio total
87
98
Book value in ¥M · ↓ reduced · ↑ increased vs prior year · M = mutual holding